Le Lézard
Classified in: Ebola virus, Health, Covid-19 virus
Subject: PSF

Texas Biomedical Research Institute in San Antonio Added to National Readiness and Preparedness Network


Move Positions Texas as Top Provider of Medical Countermeasures for Public Safety and National Security

SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- The federal agency that protects against pandemics and bioterrorism has elevated Texas Biomedical Research Institute into the top ranks of its national readiness and preparedness network.

The new designation as a prime contractor opens Texas Biomed to a portfolio of up to $100 million in funding over five years through the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. BARDA oversees advanced research and development of medical countermeasures ? vaccines, treatments and diagnostics ? for public health emergencies stemming from infectious disease outbreaks, as well as chemical, biological, radiological, and nuclear incidents and attacks.

"Texas Biomed's new partnership with BARDA will improve our ability to prevent, assess, prepare for, and respond to biological threats," said U.S. Rep. Tony Gonzales, R-San Antonio. "This move further expands Texas' significance as a leader in military and community preparedness. The jobs and innovations that will be generated from this designation will boost San Antonio's ability to compete globally in the biomedical and biotech realms."

Fewer than 15 labs nationwide ? now including Texas Biomed as the only one in the state ? are part of BARDA's Nonclinical Biological Indefinite Delivery/Indefinite Quantity (IDIQ) Network.

The network was developed in 2011 in order to better develop and bridge animal research study data to humans to provide evidence of therapy and vaccine effectiveness. It's a key element in studying medical countermeasures since efficacy of many products surrounding such critical threats often cannot be verified using human clinical studies.

"This is a huge win for San Antonio and Texas Biomed ? not to mention for the whole state," said State Sen. Jose Menendez, D-San Antonio. "San Antonio and Bexar County continue to be at the forefront of innovative techniques to protect our communities. This adds even more fuel to our thriving economic engine that's been built on biotech."

Texas Biomed is the nation's only non-profit, independent research institute with the highest-level biocontainment laboratories, a national primate research center and over 80 years of experience. Since 2015, the Institute has received about $46 million through subprime contracts with BARDA.

"The significance of this cannot be overstated ? it demonstrates Texas Biomed's ability to compete at the top level for research grants and contracts designed to keep our nation safe," said Dr. Larry Schlesinger, President & CEO.

Texas Biomed has a long history of working with federal agencies combatting national security bioterror threats. A recent example is its ongoing subcontract work with the Sabin Vaccine Institute through BARDA developing a vaccine candidate ? being deployed now ? for a variant of Ebola currently causing an outbreak in Uganda.

***

This program has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response,  (ASPR), Department of Health and Human Services (DHHS) under contract number 75A50122D00020.

Texas Biomed is a nonprofit research institute dedicated to protecting the global community from infectious diseases. Through basic research, preclinical testing and innovative partnerships, we accelerate diagnostics, therapies and vaccines for the world's deadliest pathogens. Our San Antonio campus hosts high containment laboratories and the Southwest National Primate Research Center. Our scientists collaborate with industry and researchers globally, and have helped deliver the first COVID-19 vaccine, the first Ebola treatment and first Hepatitis C therapy.

SOURCE Texas Biomedical Research Institute


These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...



News published on and distributed by: